FBR Capital Maintains an 'Underperform' on BioMed Realty Trust (BMR), However, Acquisitions Reduce Core Operating Risk
Tweet Send to a Friend
FBR Capital maintains an 'Underperform' rating on BioMed Realty Trust (NYSE: BMR), price target $19.50.
FBR analyst says, "Yesterday, BioMed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
FBR analyst says, "Yesterday, BioMed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
